Loading
Latest filing published 02 Apr 2026 for Innovent Biologics, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Zhang Qian on record concern Innovent Biologics, Inc., in the capacity of chief executive. The record holds 5 filings, for trades running from 3 May 2024 to 30 March 2026.
The open-market side counts 2 purchases alongside 1 sale for €3.1M. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2026, the count stands at 1 purchase and no sales.
Most recently, on 2 April 2026, the filings show an open-market purchase in Innovent Biologics, Inc. Filings reach the HKEX feed a median of 5 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration